Suggested remit: To appraise the clinical and cost effectiveness of diroximel fumarate within its marketing authorisation for relapsing–remitting multiple sclerosis.
 
Status In progress
Process STA 2018
ID number 1673

Project Team

Project lead Joanne Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick

Consultees

Companies sponsors Biogen Idec (diroximel fumarate)
Others Department of Health and Social Care
  NHS England
  NHS Nottingham West CCG
  NHS West Norfolk CCG
  Welsh Government
Patient carer groups Brain and Spine Foundation
  Brain Charity
  MS-UK
  Multiple Sclerosis Society
  Multiple Sclerosis Trust
  Muslim Council of Britain
  Neurological Alliance
  Shift.ms
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Sue Ryder
Professional groups Association of British Neurologists
  British Association of Neuroscience Nurses
  British Geriatrics Society
  British Neuropathological Society
  British Society for Blood and Marrow Transplantation
  British Society of Rehabilitation Medicine
  Chartered Society of Physiotherapy
  Institute of Neurology
  London MS-AHSCT Collaborative Group
  Primary Care and Community Neurology Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Occupational Therapists
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Therapists in MS
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Multiple Sclerosis Specialist Nurse Association

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Bayer (interferon beta-1b)
  Biogen Idec (dimethyl fumarate, interferon beta-1a, peginterferon beta-1a)
  Celgene (ozanimod)
  Merck (interferon beta-1a)
  Mylan (glatiramer acetate)
  Novartis (interferon beta-1b, ofatumumab)
  Roche (ocrelizumab)
  Sanofi Genzyme (teriflunomide)
  Teva UK (glatiramer acetate)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Multiple Sclerosis Wales
  National Association of Primary Care
  National Pharmacy Association
  Neurological Alliance of Scotland
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Wales Neurological Alliance
  Welsh Health Specialised Services Committee
Relevant research groups Brain Research UK
  British Neurological Research Trust
  Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
07 May 2021 NICE have taken the decision to pause this appraisal due to operational reasons, timelines are currently to be confirmed.
09 March 2021 Invitation to participate
09 March 2021 In progress. In progress
07 August 2020 - 07 September 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance